title: Incidence and mortality of liver cancer in China, 2010.
abstract: Liver cancer is a common malignant tumor in China and a major health concern. We aimed to estimate the liver cancer incidence and mortality in China in 2010 using liver cancer data from some Chinese cancer registries and provide reference for liver cancer prevention and treatment. We collected and evaluated the incidence and mortality data of liver cancer in 2010 from 145 cancer registries, which were included in the 2013 Chinese Cancer Registry Annual Report, calculated crude, standardized, and truncated incidences and mortalities, and estimated new liver cancer cases and deaths from liver cancer throughout China and in different regions in 2010 from Chinese practical population. The estimates of new liver cancer cases and deaths were 358,840 and 312,432, respectively, in China in 2010. The crude incidence, age-standardized rate by Chinese standard population (ASR China), and age-standardized rate by world standard population (ASR world) were 27.29/100,000, 21.35/100,000, and 20.87/100,000, respectively; the crude, ASR China, and ASR world mortalities were 23.76/100,000, 18.43/100,000, and 18.04/100,000, respectively. The incidence and mortality were the highest in western regions, higher in rural areas than in urban areas, and higher in males than in females. The age-specific incidence and mortality of liver cancer showed a rapid increase from age 30 and peaked at age 80-84 or 85+. Our results indicated that the 2010 incidence and mortality of liver cancer in China, especially in undeveloped rural areas and western regions, were among high levels worldwide. The strategy for liver cancer prevention and treatment should be strengthened.
authors.affiliation: Cancer Institute, Zhongshan Municipal People's Hospital, Zhongshan, Guangdong 528400, P. R. China. chenwq@cicams.ac.cn.
authors.forename: Kuang-Rong
authors.initials: KR
authors.lastname: Wei
authors.forename: Xia
authors.initials: X
authors.lastname: Yu
authors.forename: Rong-Shou
authors.initials: RS
authors.lastname: Zheng
authors.forename: Xia-Biao
authors.initials: XB
authors.lastname: Peng
authors.forename: Si-Wei
authors.initials: SW
authors.lastname: Zhang
authors.forename: Ming-Fang
authors.initials: MF
authors.lastname: Ji
authors.forename: Zhi-Heng
authors.initials: ZH
authors.lastname: Liang
authors.forename: Zhi-Xiong
authors.initials: ZX
authors.lastname: Ou
authors.forename: Wan-Qing
authors.initials: WQ
authors.lastname: Chen
mesh_terms: D002681:China / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000401:mortality; D008297:Male; D012042:Registries; D012424:Rural Population; D017678:Sex Distribution; D014505:Urban Population
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Zhonghua Yu Fang Yi Xue Za Zhi. 2010 May;44(5):383-9
references.pmid: 20654225
references.citation: Asian Pac J Cancer Prev. 2013;14(9):4953-60
references.pmid: 24175758
references.citation: Vaccine. 2009 Nov 5;27(47):6550-7
references.pmid: 19729084
references.citation: Zhonghua Zhong Liu Za Zhi. 1999 Jul;21(4):245-9
references.pmid: 11776805
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078